IP Library Granted Patent US 9,073,874
Granted Patent B2
US 9,073,874 · App. 13/811,282 · Granted Jul 7, 2015

Cyclic N,N′-diarylthioureas and N,N′-diarylureas-androgen receptor antagonists, anticancer agent, method for preparation and use thereof

Inventors: Alexandre Vasilievich Ivachtchenko (Encinitas, CA); Oleg Dmitrievich Mitkin (Moscow, RU)
C07D233/86C07D233/72C07D239/10C07D239/22C07D249/12C07D471/10C07D491/107A61K9/0019A61K9/2018A61K9/2059A61K9/2095A61K9/4858
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,073,874
App. No.
13/811,282
Granted
Jul 7, 2015
Kind
B2
Abstract

The invention relates to novel N,N′-disubstituted 2-thioxo-7-oxa-1,3-diaza-spiro[4.4]nonan-4-one-androgen receptor (AR) antagonists, an anticancer agent, a pharmaceutical composition, a medicament, and a method for treating prostate cancer. 4-[3-(4-Cyano-3-trifluoromethyl-phenyl)-4-oxo-2-thioxo-7-oxa-1,3-diaza-spiro[4.4]non-1-yl]-2-fluoro-benzamide of general formula 1 and enantiomer thereof wherein: R represents C 1 -C 3 alkyl.

Claims (7)

1. A 4-[3-(4-Cyano-3-trifluoromethyl-phenyl)-4-oxo-2-thioxo-7-oxa-1,3-diaza-spiro[4.4]non-1-yl]-2-fluoro-benzamide compound of general formula 1

wherein:

R represents C 1 -C 3 alkyl, and enantiomers thereof.

2. The compound of claim 1 , wherein the compound is 4-[(R)-3-(4-Cyano-3-trifluoromethyl-phenyl)-4-oxo-2-thioxo-7-oxa-1,3-diaza-spiro[4.4]non-1-yl]-2-fluoro-N-methyl-benzamide represented by formula (R)-1

3. A pharmaceutical composition comprising at least one 4-[3-(4-Cyano-3-trifluoromethyl-phenyl)-4-oxo-2-thioxo-7-oxa-1,3-diaza-spiro[4.4]non-1-yl]-2-fluoro-benzamide compound of general formula 1 and enantiomers thereof.

4. The pharmaceutical composition according to claim 3 and at least one pharmaceutically acceptable carrier, inert excipient or solvent.

5. The pharmaceutical composition according to claim 4 in the form of a tablet, capsule, or injection.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2015
From: IVACHTCHENKO, ALEXANDRE VASILIEVICH; IVASHCHENKO, ANDREY ALEXANDROVICH; SAVCHUK, NIKOLAY FILIPPOVICH
To: R-PHARM OVERSEAS INC.
Reel/Frame 037146/0517 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2015
From: MITKIN, OLEG DMITRIEVICH
To: IVACHTCHENKO, ALEXANDRE VASILIEVICH
Reel/Frame 035728/0785 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2013
From: IVACHTCHENKO, ALEXANDRE VASILIEVICH, DR; MITKIN, OLEG DMITRIEVICH, DR
To: IVACHTCHENKO, ALEXANDRE VASILIEVICH, DR; IVASHCHENKO, ANDREY ALEXANDROVICH, DR; SAVCHUK, NIKOLAY FILIPPOVICH, DR
Reel/Frame 029666/0047 →
Priority Claims (1)
RU 2010130618 · Jul 22, 2010 · national
Continuity (1)
Related Publication 20130116269A1 · May 9, 2013